[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-350301-105":59,"doc-detail-350301-en":130},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":123,"head_meta":125,"extra_data":127,"updated_unix":129},105,"en","lox-inhibition-disrupts-a-collagen-integrin-myc-axis-to-suppress-progression-of-invasive-lobular-carcinoma-key-study-findings","LOX Inhibition Disrupts a Collagen-Integrin-MYC Axis to Suppress Progression of Invasive Lobular Carcinoma - Key Study Findings","","LOX inhibition disrupts an extracellular matrix–integrin–MYC signaling axis to suppress progression of invasive lobular carcinoma (ILC). The work addresses limited treatment options for ILC, which is underrepresented in trials and relies on a collagen-rich niche driven by CDH1 loss. Using intraductal xenograft models and PXS-5505, a clinical pan-lysyl oxidase inhibitor, the study evaluates tumor growth, metastasis, and molecular transcriptional programs.",{"@graph":69,"@context":122},[70,84,105],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/lox-inhibition-disrupts-a-collagen-integrin-myc-axis-to-suppress-progression-of-invasive-lobular-carcinoma-key-study-findings/350301/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/lox-inhibition-disrupts-a-collagen-integrin-myc-axis-to-suppress-progression-of-invasive-lobular-carcinoma-key-study-findings/350301.png","ImageObject",300,407,{"name":92,"@type":93},"Chumphorn","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-10-23","2026-09-22",true,{"@type":102,"interactionType":103,"userInteractionCount":39},"InteractionCounter",{"@type":104},"ViewAction",{"@type":106,"mainEntity":107},"FAQPage",[108,114,118],{"name":109,"@type":110,"acceptedAnswer":111},"Why is invasive lobular carcinoma (ILC) difficult to treat?","Question",{"text":112,"@type":113},"ILC accounts for about 10% to 15% of breast cancers but lacks specific therapy because ILCs are underrepresented in clinical trials and preclinical models, and they differ from ductal cancers in clinically important ways.","Answer",{"name":115,"@type":110,"acceptedAnswer":116},"What therapeutic strategy does the study test?",{"text":117,"@type":113},"The study tests whether LOX inhibition with PXS-5505 can exploit the collagen-rich matrix dependency in ILC created by CDH1 loss, using intraductal xenograft models.",{"name":119,"@type":110,"acceptedAnswer":120},"Which molecular pathways are affected by LOX inhibition?",{"text":121,"@type":113},"Genome-wide CRISPR screens identify ITGAV and ITGB5 as synthetic lethal partners of CDH1, and LOX inhibition downregulates their expression along with MYC, NF-κB, and AP-1 transcriptional programs.","https://schema.org",{"og:url":83,"og:type":124,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":126,"canonical":83},"index,follow",{"doc_id":128,"site_id":62},350301,1790118766,{"code":4,"msg":5,"data":131},{"doc_id":128,"user_id":132,"nickname":92,"user_avatar":133,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":39,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":139,"language":140,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":67,"update_tm":144,"read_time":145,"preview_page_count":19,"preview_urls":146},2336475401981,"https://ap-avatar.wpscdn.com/avatar/22000c94efd8d5204d?x-image-process=image/resize,m_fixed,w_180,h_180&k=1786935347598174694","LOX Inhibition Disrupts a Collagen–Integrin–MYC Axis to Suppress Progression of Invasive Lobular Carcinoma  \nRene L. Flaherty1, Flavia Hughes1, George Sflomos2, Carlos Ronchi2, Harriet Kemp1,  \nTheodoros I. Roumeliotis3, Anya A. Nicholas1, Giovanna Ambrosini4,5, Amelie Ziehme1, Sarah Becker1, William W. Yang1, Yueyun Zhang2, Hazel M. Quinn2, Laura Battista2, Harveena Padda1, Solne Pezot1, Samuel Jouny1, Yanbo Liu1, Rachel Brough1, Rebecca Marlow1, Marjan Iravani1, Alicia F.C. Okines1,6, Nicholas C. Turner1,6, Athina Stravodimou7, Khalil Zaman7, Maryse Fiche8, Beatrice A. Howard1, Jyoti S. Choudhary3, Victoria Sanz-Moreno1, Clare M. Isacke1, Lara Perryman9, Wolfgang Jarolimek9, Syed Haider1, Christopher J. Lord1, and Cathrin Brisken1,2  \n|  |  | A |  | B | S |  | T | R |  | A |  | C | T |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |\n| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |\n|  | Invasive lobular carcinoma (ILC) accounts for 15% of breast cancers yet lacks specific therapy because ILCs are underrepresented in clinical trials and preclinical models are lacking. In this study, we established intraductal xenograft models to test whether the clinical pan-lysyl-oxidase inhibitor PXS-5505, now in phase I/IIa trials for myelofibrosis, can exploit the collagen-rich matrix dependency in ILC created by CDH1 loss. PXS-5505 remodeled fibrillar collagen and halted tumor expansion and metastatic seeding across estrogen receptor–positive and triple-negative models without systemic toxicity. Genome-wide CRISPR screens revealed ITGAV and ITGB5 as synthetic lethal partners of CDH1, and LOX inhibition downregulated their expression, together with MYC, NF-κB, and AP-1 transcriptional programs. Collagen fiber density/alignment and MYC/AP-1 gene signatures served aspharmacodynamic readouts of drug activity. These data uncover a tractable extracellular matrix–integrin–MYC axis in ILC and nominate PXS-5505, alone or with endocrine therapy, for window-of-opportunity trials in this understudied breast cancer subtype.\u003Cbr>Significance: A clinical stage LOX inhibitor slows tumor progression and alters multiple molecular endpoints in invasive lobular carcinoma, providing a translatable therapeutic strategy\u003Cbr>􀀶 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | for this frequent breast cancer subtype currently lacking specific therapies.\u003Cbr>\u003Cbr>Disease progression\u003Cbr>Intraductal models of ILC\u003Cbr>Patient tumor cells\u003Cbr>ECM\u003Cbr>Cell lines\u003Cbr>\u003Cbr>Cross-linking\u003Cbr>by LOX\u003Cbr>enzymes\u003Cbr>Readouts\u003Cbr>Matrix\u003Cbr>morphometrics\u003Cbr>Omics\u003Cbr>Imaging\u003Cbr>Therapeutic LOX targeting\u003Cbr>Matrix disruption\u003Cbr>PXS-5505\u003Cbr>LOX/L Cell adhesion\u003Cbr>Survival\u003Cbr>Created in BioRender. Flaherty, RL. (2026) [https://BioRender.com/2tss7o2](https://BioRender.com/2tss7o2) |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |\n\nIntroduction  \nBreast cancer is a heterogeneous disease in both histology and molecular makeup. Approximately 10% to 15% of cases are invasive lobular carcinoma (ILC), most of which are positive for estrogen receptor (ER+). ILC","cbCaiaBtSLAq2h07","https://ap.wps.com/l/cbCaiaBtSLAq2h07","pdf",26616639,21,"English","# Introduction\n## Invasive lobular carcinoma characteristics\n# Disease progression\n## Intraductal models of ILC\n## Patient tumor cells and ECM\n# Cross-linking by LOX enzymes\n## Readouts and assays\n# Therapeutic LOX targeting\n## PXS-5505 and matrix disruption","[{\"question\":\"Why is invasive lobular carcinoma (ILC) difficult to treat?\",\"answer\":\"ILC accounts for about 10% to 15% of breast cancers but lacks specific therapy because ILCs are underrepresented in clinical trials and preclinical models, and they differ from ductal cancers in clinically important ways.\"},{\"question\":\"What therapeutic strategy does the study test?\",\"answer\":\"The study tests whether LOX inhibition with PXS-5505 can exploit the collagen-rich matrix dependency in ILC created by CDH1 loss, using intraductal xenograft models.\"},{\"question\":\"Which molecular pathways are affected by LOX inhibition?\",\"answer\":\"Genome-wide CRISPR screens identify ITGAV and ITGB5 as synthetic lethal partners of CDH1, and LOX inhibition downregulates their expression along with MYC, NF-κB, and AP-1 transcriptional programs.\"}]","LOX Inhibition Disrupts a Collagen-Integrin-MYC Axis to Suppress Progression of Invasive Lobular Carcinoma - Key Study Findings | PDF",1790088315,53,[147,151,155,159],{"page_no":8,"url":148,"width":149,"height":150},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/360fcdb045b518eb1cb494a5675a0fda.webp",983,1315,{"page_no":14,"url":152,"width":153,"height":154},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/517548340bf0a17f42e8e9ea5bc40b68.webp",982,1314,{"page_no":81,"url":156,"width":157,"height":158},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/430ae281b034148e3883a28faef7a814.webp",981,1312,{"page_no":19,"url":160,"width":161,"height":162},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/3def16f1fc1765523859a9903582f10c.webp",980,1311]